A recent study identifies Neural EGFL-like 2 (NELL2), a secreted protein, as a key regulator of bone homeostasis, offering potential therapeutic applications for osteoporosis. NELL2 promotes ...
A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...
A newly discovered receptor switch that boosts bone growth could transform how we treat osteoporosis, by stimulating the body’s own bone-building machinery using a targeted drug and even mechanical ...
The From Labs to Lives Blog connects everyday topics with UC Davis research. Each post is reviewed by our experts, ensuring you always get useful information you can trust. Because we can’t see them, ...
Ultragenyx Pharmaceutical said on Monday late-stage studies showed its experimental drug for a type of genetic bone disease failed to reduce the number of fractures that occurred per year. Shares of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback